REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (389 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-06-02. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: heartrandomizationventricularpulmonaryleft
  Phrases that lowered it: screening visitthe screeningpharmacokineticsmoderatebody
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 15% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Design: parallel (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 44 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Number of arms: 3 (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Sponsor's past trials: 160 (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 0 (raises risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area
• Drug's FAERS reports before start: 0 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction NCT06237309 · started 2024 · scored riskier than 89% of active trials terminated
• Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction NCT02744339 · started 2016 · scored riskier than 70% of active trials completed
• Ranolazine in Diastolic Heart Failure NCT01163734 · started 2010 · scored riskier than 48% of active trials completed
• A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure NCT02157506 · started 2014 · scored riskier than 94% of active trials completed
• Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% NCT04435626 · started 2020 · scored riskier than 56% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.